Cellceutix Matriculates to Harvard
 


     
   
 


Note I will be posting an interview with the CEO next week, where we will discuss more about the company and valuation. Stay tuned!
Hedging Biotech Risk with Strong Potential Puts Cellceutix in Limelight
The speculative nature of biotechnology investing makes it one of the most intriguing industries in the markets.  The true beauty of a successful drug is not only the ludicrous amount of revenue that can be generated for the company, building strong value for its shareholders, but the fact that there are compelling humanitarian benefits as well.  Sifting through the thousands of drugs in development and the companies researching them is all too often a daunting task.  After all, each biotech earnestly is attempting to develop a significant breakthrough.  News hit the wires this week from Cellceutix Corporation (OTCBB: CTIX), a near clinical stage biotech, that certainly separated the company from its many peers and commanded a closer look.
With even the quickest glimpse, Cellceutix looks different than other developmental biotechs.  A robust portfolio containing eight compounds for a variety of diseases and a scientific team that includes Dr. Emil Frei, “the father of the cure for childhood leukemia�; Dr. Krishna Menon, a lead researcher for the blockbuster cancer drugs Alimta and Gemzar; and Dr. Samuel Danishefsky, a Wolf Award winner and Chairman of the Laboratory for Cancer Research Bioorganic Chemistry at Memorial Sloan-Kettering Cancer Center.
Kevetrin, Cellceutix’s flagship compound, is being developed as a completely new class of chemistry that has demonstrated potent anti-tumor properties across a wide array of cancer strains in pre-clinical studies.  The company’s research has shown that Kevetrin re-activates p53, a key tumor suppressor protein that is often called “the Guardian Angel of the Human Genome.�  In more than 50 percent of all cancers, p53 is either damaged or mutated, stopping the… Read the rest
               More on this topic
                  (What's this?)
                        6 Deeply Undervalued Biotech Companies
                        (Investment Underground » Page n..., 9/16/11)
                        This Biotech Discovery Causes HIV to Self-Destruct
                        (Wall Street Daily, 8/22/11)
                        6 Deeply Undervalued Biotech Stocks
                        (Investment Underground » Page n..., 7/29/11)
                        Is There Such Thing as a Reliable Small-Cap Biotech Stock?
                        (Benzinga, 11/4/11)
                           Read more on
                                 Cellceutix,
                                 Biotechnology
                           at Wikinvest
   

   
           
                     
              Shared: 
                    Twitter: 0 LinkedIn: 0 Facebook: 0        
       

Original news source


 

 

http://www.valueinvestingnews.com/cellceutix-matriculates-harvard